Budget Amount *help |
¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000)
Fiscal Year 2014: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2013: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2012: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
Outline of Final Research Achievements |
Elucidating the mechanisms of neuronal apoptosis and its prevention is crucial for the development of a new therapeutic strategy for stroke. Glucagon-like peptide 1 (GLP-1) agonist; exendrin-4 showed a tendency to decrease the amount of apoptosis cells in the CA1 region of the rat hippocampus after transient forebrain ischemia. In addition, the number of Ki67 positive cells tends to increase in the group injected exendrin-4. Thus, theses results suggest that exendrin-4 has neuroprotective effect and regulates neuronal regeneration under physiological and ischemic conditions.
|